FIELD: medicine.
SUBSTANCE: claimed invention relates to field of medications, in particular to peroral mediations with retarded release, which contain at least 20 mgA of ziprazidone and substance ensuring retarded release. In addition invention relates to methods of treating patient by introduction of said dosage forms.
EFFECT: in ensuring efficient levels of ziprazidone in blood during long period of time.
44 cl, 2 dwg, 15 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL DEPOT-PREPARATIONS FOR INJECTION | 2003 |
|
RU2310450C2 |
| MEDICINAL CONTROLLED-RELEASING FORMS OF AZITHROMYCIN | 1995 |
|
RU2130311C1 |
| ORAL DOSAGE FORMS OF TOFACITINIB WITH CONTINUOUS RELEASE | 2014 |
|
RU2790166C2 |
| GUANFACINE-BASED PHARMACEUTICAL COMPOSITIONS, SUITABLE FOR DAILY INTRODUCTION IN FORM OF SINGLE DOSED FORM | 2006 |
|
RU2435573C2 |
| NIACIN-CONTAINING PHARMACEUTICAL COMPOSITION (VERSIONS) AND TABLET PREPARATION, METHOD FOR REDUCING HYPEREMIA AND METHOD FOR PREPARING NIACIN-CONTAINING TABLET | 2007 |
|
RU2467750C2 |
| PHARMACEUTICAL COMPOSITIONS CONSISTING OF MULTIPLE PARTICLES WITH SUSTAINED-RELEASE OF SEROTONIN REUPTAKE SELECTIVE INHIBITOR | 2000 |
|
RU2275191C2 |
| PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2316324C2 |
| DEPO-PREPARATIONS OF ACTIVE ARYLHETEROCYCLIC SUBSTANCES IN SLURRY FORM | 2003 |
|
RU2292207C2 |
| TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS | 2014 |
|
RU2674345C2 |
| SLOW-RELEASE TABLET WITH SPECIFIED CORE GEOMETRY | 2004 |
|
RU2391093C2 |
